The Summary
In this double-blind RCT, researchers evaluated the effects of chicory-derived inulin-type fructans in 56 patients with mild psoriasis, using 32 healthy individuals as a baseline. Participants took 15 grams of prebiotics or a placebo daily for eight weeks. While psoriasis patients exhibited higher baseline metabolic risks, the prebiotic group successfully maintained stable fasting blood glucose and resting metabolic rates. In contrast, the placebo group (receiving maltodextrin) experienced a decline in metabolic indices, highlighting the potential protective role of prebiotics against metabolic worsening in chronic inflammatory states.
Why this is interesting
Psoriasis is typically viewed as just a skin condition, but it is actually a systemic inflammatory disease linked to metabolic issues like insulin resistance. This study is exciting because it shows that a simple dietary prebiotic might shield psoriasis patients from metabolic decline. However, there is a catch: the placebo (maltodextrin) may have actively worsened the control group's health. For readers, this emphasizes the importance of dietary fibers like inulin in managing systemic inflammation, while cautioning against common food additives like maltodextrin that could disrupt metabolic balance.